Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Equities researchers at Desjardins reduced their FY2024 EPS estimates for Inovalis Real Estate Investment Trust in a research report issued on Monday, November 11th. Desjardins analyst A. Leon now forecasts that the company will post earnings of $0.01 per share for the year, down from their prior forecast of $0.06.
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The firm had revenue of C$3.52 million for the quarter.
Inovalis Real Estate Investment Trust Stock Performance
Inovalis Real Estate Investment Trust Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Articles
- Five stocks we like better than Inovalis Real Estate Investment Trust
- Industrial Products Stocks Investing
- Rocket Lab is the Right Stock for the Right Time
- Are Penny Stocks a Good Fit for Your Portfolio?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Profitably Trade Stocks at 52-Week Highs
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.
